Abstract
Previous data have indicated that T-type calcium channels (low-voltage activated T-channels) are potently inhibited by volatile anesthetics. Although the interactions of T-channels with a number of anesthetics have been described, the mechanisms by which these agents modulate channel activity, and the functional consequences of such interactions, are not well studied. Here, we used patch-clamp recordings to explore the actions of a prototypical volatile anesthetic, isoflurane (Iso), on recombinant human CaV3.1 and CaV3.2 isoforms of T-channels. We also performed behavioral testing of anesthetic endpoints in mice lacking CaV3.2. Iso applied at resting channel states blocked current through both isoforms in a similar manner at clinically relevant concentrations (1 minimum alveolar concentration, MAC). Inhibition was more prominent at depolarized membrane potentials (-65 versus -100 mV) as evidenced by hyperpolarizing shifts in channel availability curves and a 2.5-fold decrease in IC50 values. Iso slowed recovery from inactivation and enhanced deactivation in both CaV3.1 and CaV3.2 in a comparable manner but caused a depolarizing shift in activation curves and greater use-dependent block of CaV3.2 channels. In behavioral tests, CaV3.2 knockout (KO) mice showed significantly decreased MAC in comparison with wild-type (WT) litter mates. KO and WT mice did not differ in loss of righting reflex, but mutant mice displayed a delayed onset of anesthetic induction. We conclude that state-dependent inhibition of T-channel isoforms in the central and peripheral nervous systems may contribute to isoflurane's important clinical effects.
Footnotes
-
This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant GM070726] and the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant F31-NS059190].
-
ABBREVIATIONS: DRG, dorsal root ganglion; HVA (high-voltage-activated); Iso, isoflurane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane); Hal, halothane, 2-bromo-2-chloro-1,1,1-trifluoroethane; MAC, minimum alveolar concentration; LORR, loss of righting reflex; TTLORR, time to loss of righting reflex; KO, knockout; WT, wild type; HEK, human embryonic kidney; CNS, central nervous system.
- Received August 29, 2008.
- Accepted November 26, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|